Table 1.
Comparison of Patient Characteristics Between Study (“COVID”) Cohort and 2018 to 2019 (“Pre-COVID”) Cohort
| “Pre-COVID” cohort | “COVID” cohort | P | |
|---|---|---|---|
| Total number of patients | 613 | 151 | |
| Age, median (range) | 54 (0-74) | 53 (0-75) | .827 |
| Diagnosis, n (%) | |||
| AML | 262 (43) | 65 (43)* | .768 |
| ALL | 90 (15) | 17 (11) | |
| MDS | 105 (17) | 28 (19) | |
| MPN | 42 (7) | 9 (6) | |
| Lymphoma | 72 (12) | 17 (11) | |
| Bone marrow failure syndromes | 21 (3) | 5 (3) | |
| Immunodeficiency | 13 (2) | 3 (2) | |
| Other | 8 (1) | 3 (2) | |
| ATG given, n (%) | |||
| Yes | 373 (61%) | 99 (70%)† | .038 |
| No | 240 (39%) | 42 (30%) | |
| MTX-based GVHD prophylaxis, n (%) | |||
| Yes | 520 (81%) | 126 (89%)† | .166 |
| No | 93 (15%) | 15 (11%) | |
| Stem cell source, n (%) | |||
| HPC (A) | 552 (90%) | 148 (98%) | .002 |
| HPC (M) | 61 (10%) | 3 (2%) | |
| Regimen intensity, n (%) | |||
| Myeloablative | 230 (38%) | 49 (35%)‡ | .503 |
| Reduced intensity | 383 (63%) | 93 (66%) | |
| Time to neutrophil recovery, median (IQR) | 17 (10-24) | 17 (10 – 24) | .540 |
| Neutrophil recovery by day 28, cumulative incidence (95% confidence interval) | 90 (89-92%) | 92 (90–95%) | .521 |
| Time to platelet recovery, median (IQR) | 20 (9-31) | 21 (8-34) | .123 |
| Platelet recovery by day 60, cumulative incidence (95% confidence interval) | 87 (86-88%) | 92 (89-95%) | .755 |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplasia including myeloproliferative/myelodysplastic overlap conditions; MPN, myeloproliferative neoplasms; IQR, interquartile range.
* 4 cases missing data.
†10 cases missing data.
‡9 cases missing data.